1. Health
You can opt-out at any time. Please refer to our privacy policy for contact information.

Discuss in my forum

Carol Eustice

FDA Approves Otezla (apremilast) for Psoriatic Arthritis

By March 21, 2014

Follow me on:

The FDA has announced the approval of Otezla (apremilast) for the treatment of active psoriatic arthritis in adults. Otezla is an inhibitor of phosphodiesterase-4 (PDE-4). PDE4 inhibition results in increased intracellular cAMP levels (cyclic adenosine monophosphate).

The safety and effectiveness of the drug was evaluated in three clinical trials (PALACE 1, 2, and 3) involving 1,493 patients with active psoriatic arthritis. Compared to placebo, study participants treated with Otezla showed improvement in signs and symptoms, including tender and swollen joints and physical function.

Patients taking Otezla should watch for signs of unexplained weight loss or depression. Common side effects included diarrhea, nausea, and headache. The oral drug is manufactured by Celgene. Availability in the U.S. is expected to be in March 2014 through a network of specialty pharmacies. Look for more information at otezla.com.

More About Psoriatic Arthritis

Connect With Carol:

Facebook | Twitter | Google+ | Message Board | Newsletter

Photo by Tina Lorien (iStockphoto)

Comments
April 13, 2014 at 2:31 am
(1) sallie fendley says:

You are very much appreciated for your wealth of information you give us. It is so helpful to have a part in helping our doctor be able to treat us using some of you information you make available . Thank you! Thank you! Thank you!

Leave a Comment

Line and paragraph breaks are automatic. Some HTML allowed: <a href="" title="">, <b>, <i>, <strike>

©2014 About.com. All rights reserved.

We comply with the HONcode standard
for trustworthy health
information: verify here.